(CercleFinance.com) – GSK will present 25 abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7) and nine abstracts at the 2022 European Hematology Association (EHA) Hybrid Congress ) (June 9-12) focused on approved therapies, Blenrep (belantamab mafodotin), Jemperli (dostarlimab) and Zejula (niraparib), as well as its experimental drugs.
“The data presentations further demonstrate the company’s commitment to evaluating its approved and investigational therapies alone and in combination with other treatments and to exploring potential opportunities to improve patient care,” the group states.
Hesham Abdullah, Senior Vice President, Global Head of Oncology Development at GSK, said: ‘We have strategically built a portfolio and pipeline that leverages immune system science, human genetics and cutting-edge technologies to treat a variety of tumor types. ‘
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
